🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hangzhou
Clinical trial register · China

Clinical Trials in Hangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine373 Zhejiang University104 First Affiliated Hospital of Zhejiang University103 AstraZeneca76 Zhejiang Cancer Hospital63
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Hangzhou

1812 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Leukemia
NCT06902025B-ALL
He Huang
Not applicable
24
Hangzhou
2025-03-31
Recruiting
Efficacy and Safety Comparison of Cofrogliptin Add-on Versus Metformin Dose-escalation in Type 2 Diabetes Patients Inadequately Controlled With SGLT-2 Inhibitors Plus Low-Dose Metformin:A Multicenter, Open-Label Trial
NCT06863532Type 2 Diabetes
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
80
Hangzhou
2025-03-30
Not yet open
Association of Sleep Quality With Pathologic Staging, Acupuncture Treatment in Patients With Chronic Atrophic Gastritis: a Cross-sectional Study
NCT06912178Chronic Atrophic Gastritis (CAG)
Yi Liang
Observational
120
Hangzhou
2025-03-30
Recruiting
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
NCT06750289Eosinophilic Asthma
AstraZeneca
Phase 3
400
Beijing, Changsha, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Huizhou
2025-03-28
Active, closed
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
NCT06867094Colitis Ulcerative
Sanofi
Phase 2
204
Guangzhou, Hangzhou, Huizhou, Jiazhuang, Linhai, Luoyang, Shanghai, Wuhan
2025-03-28
Recruiting
HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients
NCT06770452Metastatic Pancreatic Carcinoma
Zhejiang University
Phase 2
133
Hangzhou
2025-03-25
Recruiting
Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)
NCT06977893HR+/HER2- Breast Cancer
First Affiliated Hospital of Zhejiang University
Phase 3
194
Hangzhou, Harbin, Hefei, Jinhua, Nanchang, Nantong, Shanghai, Ürümqi
2025-03-24
Recruiting
QL1706 Combined With SOX Used in Theperioperative Treatment
NCT06766305Gastric Cancers, Esophagogastric Junction Cancers
Xiangdong Cheng
Phase 1/2
54
Hangzhou
2025-03-21
Recruiting
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
NCT06914128MTAP-deleted Solid Tumors
Bayer
Phase 1/2
450
Beijing, Wuhan, Nanjing, Hangzhou
2025-03-21
Active, closed
cOncomitant Left Atrial aPpendage Closure and Pulsed Field ablaTION-Asia
NCT06686485Concomitant Procedures, Atrial Fibrillation, PFA, LAAC
Boston Scientific Corporation
Observational
433
Suzhou, Beijing, Chengdu, Guangzhou, Guiyang, Hangzhou, Jinan, Kunming
2025-03-18
Recruiting
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878Moderately to Severely Active Crohns Disease
Hoffmann-La Roche
Phase 3
600
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2025-03-17
Recruiting
A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome
NCT06304103Myelodysplastic Syndromes
Kind Pharmaceuticals LLC
Phase 2
63
Hangzhou
2025-03-14
Recruiting
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
NCT06869551Juvenile Psoriatic Arthritis
Bristol-Myers Squibb
Phase 3
60
Beijing, Chongqing, Guangzhou, Nanjing, Changchun, Hangzhou, Shanghai
2025-03-13
By invitation
A Phase III Clinical Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis.
NCT07180511Atopic Dermatitis (AD)
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
Phase 3
460
Hangzhou
2025-03-12
Recruiting
Effect of Bone Augmentation Simultaneous to Implant Removal on the Prognosis of Reimplantation at the Same Site
NCT07078890Implant Failure, Bone Augmentation, Prognosis
The Dental Hospital of Zhejiang University School of Medicine
Not applicable
40
Wuhan, Hangzhou, Shanghai
2025-03-12
Recruiting
Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma
NCT07022223Marginal Zone Lymphoma(MZL)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
51
Hangzhou, Dongyang, Huzhou, Jiaxing, Lishui, Ningbo, Quzhou, Shaoxing
2025-03-11
Recruiting
Drug-induced Kidney Injury Model
NCT06939387Acute Kidney Injury
Zhejiang Provincial People's Hospital
Observational
1,500
Hangzhou
2025-03-10
Recruiting
Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial
NCT07167160Cervical Cancer, Immunochemotherapy
Women's Hospital School Of Medicine Zhejiang University
Phase 2
59
Hangzhou
2025-03-10
Recruiting
A Study to Evaluate the Safety, Tolerability and PK of SK-08
NCT07021157Chronic Kidney Disease(CKD)
Consun Pharmaceutical Group
Phase 1
48
Hangzhou
2025-03-09
Not yet open
Observation on the Curative Effect of Acupuncture At Sensitized Points on Gallbladder Meridian in the Treatment of Neck Type Cervical Spondylopathy
NCT06847945Cervical Spondylopathy
LiChaoran
Not applicable
80
Hangzhou
2025-03-05
Recruiting
The Parkinson's Disease Case-Control Study
NCT06848192Parkinson Disease
Westlake University
Observational
40
Hangzhou
2025-03-05
Recruiting
Neoadjuvant High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab and Chemotherapy for ER-Positive /HER2-Negative Breast Cancer
NCT06964906ER+/HER2- Breast Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
30
Hangzhou
2025-03-04
Recruiting
The Study Evaluating the Improvement of Nutritional Status and Frailty With Silkworm Pupa Powder Among Patients With Motor Neuron Disease
NCT06765499Motor Neuron Disease (MND), Amyotrophic Lateral Sclerosis (ALS)
First People's Hospital of Hangzhou
Not applicable
100
Hangzhou
2025-03-04
Active, closed
Blended Cardiac Rehabilitation Training for Cardiology Residents
NCT07755878Medical Education, Cardiac Rehabilitation
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
98
Hangzhou
2025-03-03
Not yet open
The Use of Hydrogen Ion Water (Shan Shang Water) in the Treatment of Allergic Rhinitis
NCT06756243Allergic Rhinitis
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
100
Hangzhou
2025-03-01
Not yet open
Effectiveness and Safety of InO±DLI for Relapsed B-ALL/LBL After Allo-HSCT
NCT06861348Leukemia, Lymphocytic, Acute
First Affiliated Hospital of Zhejiang University
Phase 2
23
Hangzhou
2025-03-01
Active, closed
Adjunctive Yu-Tone Music Therapy for Systemic Lupus Erythematosus: a Prospective Cohort Study
NCT06898489Systemic Lupus Erythematosus, Music Therapy
Yijun Luo
Observational
160
Hangzhou
2025-03-01
Recruiting
Sleeve Lobectomy for Lung Cancer in Minimally Invasive Surgical Techniques
NCT06687408Lung Cancer, Non-Small Cell
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
450
Hangzhou, Shanghai
2025-03-01
Not yet open
Study of Sinibolimab Combined with Lenvatinib As Neoadjuvant Therapy for Locally Advanced Unresectable Differentiated Thyroid Carcinoma
NCT06848920Differentiated Thyroid Carcinoma (DTC), Neoadjuvant Therapy
Zhejiang University
Phase 2
20
Hangzhou
2025-03-01
Not yet open
Intravenous Thrombolytic Therapy for Acute Ischemic Stroke Patients with Low NIHSS and Non-disabling Deficits
NCT06115070Thrombosis, Acute Ischemic Stroke (AIS)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
390
Hangzhou
2025-03-01
Recruiting
Effect of the Combined Application of Cynara Scolymus, Silybum Marianum, Curcuma Longa, and Glycyrrhiza Glabra in Improving Metabolic Associated Fatty Liver Disease : a Randomized Clinical Trial
NCT06798948Metabolic-associated Fatty Liver Disease (MAFLD)
Li Lab,MD
Phase 2
100
Hangzhou
2025-03-01
Recruiting
Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma
NCT06741020Hepatocellular Carcinoma (HCC)
Zhejiang Cancer Hospital
Phase 1/2
10
Hangzhou
2025-03-01
Recruiting
Epidural Electrical Stimulation in Spinal Cord Injury
NCT07105878Spinal Cord Injuries (SCI)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
10
Hangzhou
2025-03-01
By invitation
Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System Lymphoma
NCT06827782Refractory/Recurrent Central Nervous System Lymphoma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1
42
Hangzhou
2025-03-01
Not yet open
The Safety and Efficacy of Intravenous EXG110 in Patients With Fabry Disease
NCT06819514Fabry Disease
Guangzhou Jiayin Biotech Ltd
Phase 1/2
16
Nanjing, Hangzhou
2025-03-01
Not yet open
A Single-blind, Randomized, Controlled Clinical Study of Flash Stimulation Therapy in Parkinson's Disease
NCT06848621Parkinson's Disease
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
48
Hangzhou
2025-03-01
Not yet open
JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Lymphoma
NCT06879470B-Non Hodgkin Lymphoma
He Huang
Not applicable
24
Hangzhou
2025-03
Recruiting
An Exploratory Study to Confirm Efficacy of Modified Deep Cervical Lymphovenous Anastomosis (LVA) in Alzheimer's Disease/ Parkinson's Disease
NCT06852352Alzheimer Disease, Parkinson Disease
Zhejiang Provincial People's Hospital
Not applicable
160
Hangzhou
2025-02-28
Recruiting
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
NCT06780137Small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 1/2
327
Beijing, Fuzhou, Nanjing, Shanghai, Chengdu, Hangzhou
2025-02-27
Recruiting
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
NCT06731478Gastric Cancer, Gastroesophageal Junction Cancer
Daiichi Sankyo
Phase 3
726
Beijing, Changzhou, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou
2025-02-27
Recruiting
Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
NCT06846996HER2-positive Gastric Cancer, HER2-positive Gastroesophageal Junction
Daiichi Sankyo
Observational
260
Beijing, Changchun, Changzhi, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei
2025-02-27
Recruiting
SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
NCT06873659Solid Tumor, Gastric Cancer, Liver Cancer
Qurgen Inc.
Phase 1
96
Beijing, Lanzhou, Guangzhou, Nanjing, Xi'an, Jinan, Shanghai, Hangzhou
2025-02-26
Recruiting
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
NCT06741644Advanced Solid Tumors
CStone Pharmaceuticals
Phase 1/2
800
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2025-02-24
Not yet open
Clinical Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of ATC
NCT06856278Anaplastic Throid Carcinoma
Zhejiang Provincial People's Hospital
Phase 1/2
30
Hangzhou
2025-02-22
Recruiting
Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
NCT06809764Non-small Cell Lung Cancer
Daiichi Sankyo
Observational
150
Beijing, Changsha, Fuzhou, Guangdong, Guangzhou, Hangzhou, Hebei, Hefei
2025-02-21
Not yet open
Impact of Thyroid Treatment on Ovarian Function and Pregnancy Outcomes in Women with Differentiated Thyroid Cancer
NCT06845098Thyroid Gland
Zhejiang Provincial People's Hospital
Not applicable
300
Hangzhou
2025-02-20
Recruiting
A Study Evaluating the Effect of Aumolertinib on the Pharmacokinetics of Midazolam in Patients With NSCLC
NCT06926413Non Small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1
20
Hangzhou
2025-02-20
Active, closed
Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01
NCT06727565Head and Neck Squamous Cell Carcinoma
Gilead Sciences
Phase 2
39
Chengdu, Hangzhou, Nanning, Shanghai, Wuhan
2025-02-18
Recruiting
Head-to-head Study of Tegoprazan 50 mg BID Plus Amoxicillin 1 g TID vs. Vonoprazan 20 mg BID Plus Amoxicillin 1 g TID for H. Pylori Eradication
NCT07242456Helicobacter Pylori Infection
First People's Hospital of Hangzhou
Phase 2/3
240
Hangzhou
2025-02-17
Recruiting
Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL
NCT06832267Primary Central Nervous System Lymphoma
Zhejiang Cancer Hospital
Not applicable
44
Hangzhou
2025-02-14
Recruiting
Accurate Assessment and Intervention Research on Newborn Whole Genome Sequencing and Genetic Disease Risk
NCT07365254Genetic Disease
Women's Hospital School Of Medicine Zhejiang University
Observational
1,000,000
Hangzhou
2025-02-14
Recruiting
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06760819Advanced Solid Tumors, HER2 Mutation
Bayer
Phase 2
111
Beijing, Changsha, Shanghai, Hangzhou
2025-02-13
By invitation
Correlation Between CEUS Identification of Nodular HPD on CE-MRI and Hepatic Malignant Lesions
NCT06816212Hepatic Malignant Tumors, Hepatic Perfusion Disorders
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
280
Hangzhou
2025-02-10
Recruiting
Remimazolam Besylate in Sedation of Postcardioperative Patients
NCT06716840Remimazolam, Propofol, Sedation, Mechanical Ventilation
First Affiliated Hospital of Zhejiang University
Not applicable
120
Hangzhou
2025-02-10
Recruiting
A Prospective Observational Study on the Efficacy and Safety of Guselkumab in the Treatment of Crohn's Disease Patients Previously Treated With Ustekinumab
NCT07487480Inflamatory Bowel Disease, Inflamatory Bowel Disease (Crohn's and Ulcerative Colitis)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
60
Hangzhou
2025-02-10
Recruiting
SBRT Plus Lenalidomide for Solitary Plasmacytoma: Phase II Trial
NCT06863584Solitary Plasmacytoma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
41
Hangzhou
2025-02-10
Not yet open
Clinical Study on the Safety and Efficacy of Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy for Adult Relapsed/Refractory Acute Myeloid Leukemia.
NCT06786299Relapsed/Refractory Acute Myeloid Leukemia(AML)
First Affiliated Hospital of Zhejiang University
Phase EARLY_PHASE1
18
Hangzhou
2025-02-10
Not yet open
Clinical Classification of MAFLD Based Liver Biopsy
NCT06795646Metabolic Dysfunction Associated Steatotic Liver Disease, Metabolic Dysfunction-associated Steatohepatitis (MASH)
Beijing Friendship Hospital
Observational
2,000
Beijing, Hangzhou, Shanghai, Tianjin
2025-02-08
Active, closed
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834360Chronic Rhinosinusitis With Nasal Polyps
Sanofi
Phase 3
216
Baotou, Beijing, Chengdu, Chongqing, Hangzhou, Jinan, Jingzhou, Nanning
2025-02-06
Recruiting
Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation
NCT07003737Acute Lymphoblastic Leukemia, B-precursor
First Affiliated Hospital of Zhejiang University
Not applicable
114
Hangzhou
2025-02-05
Recruiting
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
NCT06624670Pyoderma Gangrenosum
LEO Pharma
Phase 3
90
Beijing, Changchun, Changsha, Chengdu, Hangzhou, Jinan, Shanghai, Shenzhen
2025-02-05
Recruiting
18F-mFBG PET Imaging in the Evaluation of Neuroblastoma
NCT06852807Neuroblastoma
First Affiliated Hospital of Zhejiang University
Observational
200
Hangzhou
2025-02-04
Recruiting
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
NCT06756932Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
BeOne Medicines
Phase 1
120
Guangzhou, Zhengzhou, Shanghai, Tianjin, Hangzhou
2025-02-04
Recruiting
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
NCT06712355Extensive-stage Small-cell Lung Cancer
BioNTech SE
Phase 3
621
Changchun, Baoding, Beijing, Bengbu, Fuzhou, Guangzhou, Hangzhou, Ha’erbin
2025-02-03
Recruiting
The Study About the Identification of Treatable Traits of Severe Asthma and the Construction of Personalized Treatment System
NCT07136025Asthma
Beijing Chao Yang Hospital
Not applicable
200
Beijing, Guangzhou, Zhengzhou, Changsha, Shenyang, Shanghai, Taiyuan, Hangzhou
2025-02-01
Recruiting
Phase II Trial of Albumin-Bound Paclitaxel Combined With Nedaplatin (TP) Via Hepatic Arterial Infusion for Advanced Breast Cancer Patients With Liver Metastases After Failure of Standard Therapy
NCT07284836Hepatic Artery Infusion, Liver Metastasis of Breast Cancer
Zhejiang Cancer Hospital
Phase 2
30
Hangzhou
2025-02-01
Recruiting
To Investigate the Real-world Efficacy and Safety of Sacituzumab Govitecan for HER2 Negative Metastatic Breast Cancer Patients in China.
NCT06784921Breast Cancer Metastatic
Zhejiang Cancer Hospital
Observational
200
Hangzhou
2025-02-01
Recruiting
A Study of SCTB35 in Patients with Systemic Lupus Erythematosus
NCT06841042System Lupus Erythematosus
Sinocelltech Ltd.
Phase 1/2
168
Beijing, Changchun, Guangzhou, Hangzhou, Jiujiang, Kunming, Linfen, Mianyang
2025-02
Recruiting
CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis
NCT06785519Lupus Nephritis
He Huang
Phase EARLY_PHASE1
9
Hangzhou
2025-01-31
Recruiting
CD7 CAR-T Cell Sequential Allo-HSCT for Non-malignant Blood and Immune System Diseases
NCT06787560Bone Marrow Failure Syndrome
Zhejiang University
Phase EARLY_PHASE1
20
Hangzhou
2025-01-31
Recruiting
Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia
NCT06793241B-cell Acute Lymphoblastic Leukemia
Zhejiang University
Phase EARLY_PHASE1
15
Hangzhou
2025-01-31
Not yet open
A Registry Study Assessing PRO, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic Diseases.
NCT06766552Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA), Nr-axSpA, Polymyalgia Rheumatica (PMR)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
10,000
Hangzhou
2025-01-30
Recruiting
Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell Sequential Allo-HSCT and Kidney Transplantation in the Treatment of SIOD
NCT06769191Schimke Immuno-osseous Dysplasia
Zhejiang University
Phase EARLY_PHASE1
20
Hangzhou
2025-01-30
Recruiting
Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease
NCT06792799Autoimmune Diseases, Systemic Lupus Erthematosus, Multi-Drug Resistant Nephrotic Syndrome, IgAN - IgA Nephropathy
The Children's Hospital of Zhejiang University School of Medicine
Phase EARLY_PHASE1
36
Hangzhou
2025-01-30
Active, closed
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
EMD Serono Research & Development Institute, Inc.
Phase 1/2
184
Hefei, Beijing, Guangzhou, Wuhan, Harbin, Changsha, Chengdu, Hangzhou
2025-01-29
Recruiting
Characterization of Gut and Tongue Coating Microbiota in Patients With Diminished Ovarian Reserve
NCT07124260Diminished Ovarian Reserve
Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University
Observational
200
Hangzhou
2025-01-28
Recruiting
Intravenous Thrombolysis and NOAC
NCT06749834Acute Ischemic Stroke
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 3
280
Hangzhou, Taizhou
2025-01-27
Recruiting
The Impact of Fexofenadine Hydrochloride on the Prognosis of Patients Post-Acute Myocardial Infarction
NCT07381803Zhejiang University
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 3
2,804
Hangzhou
2025-01-27
Active, closed
A Study to Evaluate the Safety and Effectiveness of Mirogabalin in Chinese Adult Patients With Diabetic Peripheral Neuropathic Pain (DPNP) in Real-world Clinical Practice Setting (ReMIssion Study)
NCT06812117Diabetic Peripheral Neuropathic Pain
Daiichi Sankyo
Observational
721
Beijing, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Hangzhou
2025-01-24
Active, closed
A Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients
NCT06764303Paroxysmal Nocturnal Hemoglobinuria
Nanjing Chia-tai Tianqing Pharmaceutical
Phase 2
24
Tianjin, Hangzhou
2025-01-23
Recruiting
Effect and Safety of Fexofenadine Hydrochloride vs Placebo in Patients With Acute Myocardial Infaction: A Randomized Clinical Trial
NCT06548204ST-segment Elevation Myocardial Infarction (STEMI)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
160
Hangzhou
2025-01-20
Recruiting
The Safety and the Efficiency of Hyperbaric Oxygen in Traumatic Brain Injury
NCT06816199Traumatic Brain Injury
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
300
Hangzhou
2025-01-20
Not yet open
Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer
NCT06759090Metastatic Pancreatic Carcinoma
Zhejiang University
Phase 2
43
Hangzhou
2025-01-15
By invitation
GCB-001 in Treatment of Patients With Type II (SMA) Spinal Muscular Atrophy
NCT06772402Spinal Muscular Atrophy Type 2
Genecombio Ltd.
Not applicable
6
Hangzhou
2025-01-15
Recruiting
IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors
NCT06349408Locally Advanced Solid Tumor
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
250
Beijing, Shanghai, Hangzhou
2025-01-10
Recruiting
Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma
NCT06676982Advanced Hepatocellular Carcinoma
Zhejiang University
Phase 1
12
Hangzhou
2025-01-10
Recruiting
A Clinical Study to Explore the Safety and Efficacy of CD33 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia
NCT06762132Acute Myeloid Leukemia
Zhejiang University
Phase EARLY_PHASE1
27
Hangzhou
2025-01-10
Not yet open
A Study of CAR-T Cells in Subjects with Autoimmune Diseases
NCT06762119Autoimmune Diseases
Zhejiang University
Phase EARLY_PHASE1
6
Hangzhou
2025-01-10
Recruiting
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
NCT06712316Non-small Cell Lung Cancer
BioNTech SE
Phase 2/3
1,580
Baoding, Beijing, Changchun, Hangzhou, Jinan, Kunming, Nanjing, Shanghai
2025-01-07
Recruiting
SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Cancer
NCT06864013Locally Advanced Rectal Cancer (LARC)
First Affiliated Hospital of Zhejiang University
Phase 2
116
Hangzhou
2025-01-06
Recruiting
Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases
NCT06614270Systemic Sclerosis (SSc), ANCA Associated Vasculitis (AAV), Idiopathic Inflammatory Myopathy (IIM), Sjogren's Syndrome
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
15
Hangzhou
2025-01-06
Recruiting
Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis
NCT06375005Diffuse Cutaneous Systemic Sclerosis
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
38
Yangzhou, Shanghai, Hangzhou, Huzhou, Jiaxing, Ningbo, Wenzhou
2025-01-06
Recruiting
Personalized DBS Targeting for Treating Depression
NCT06784388Treatment-resistant Depression (TRD)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase EARLY_PHASE1
5
Hangzhou
2025-01-05
Recruiting
The Effect of Combined Iron Protocols on Perioperative Allogeneic Transfusion
NCT06012760Anemia, Iron Deficiency Anemia, Perioperative, Transfusion
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
400
Hangzhou
2025-01-04
Recruiting
Exploratory Study on the Efficacy of Betaine Hydrochloride in Treating Autoimmune Gastritis
NCT06881511Autoimmune Gastritis
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
100
Hangzhou
2025-01-03
Not yet open
A Study of Silkworm Pupa Powder Intervention in the Nutritional Status of Patients with Alzheimer's Disease.
NCT06770309Alzheimer Disease (AD), Sarcopenia, Asthenia
Yanbu Ke
Not applicable
100
Hangzhou
2025-01-02
Not yet open
Effects of Vitamin D Supplementation on Postoperative Rehabilitation in Hip and Knee Osteoarthritis Patients
NCT06747559Osteoarthritis of the Hip or Knee, Joint Arthroplasty
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
300
Hangzhou
2025-01-01
Recruiting
AI-Enabled Diagnosis and Prognosis of Hypertrophic Cardiomyopathy
NCT07263204Hypertrophic Cardiomyopathy (HCM), Left Ventricular Hypertrophy
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
15,000
Hangzhou
2025-01-01
Recruiting
Enhanced Adjuvant Therapy for Newly Diagnosed GBM With Partial Surgical Resection or Short-term Progression
NCT06936046Glioblastoma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
200
Hangzhou
2025-01-01
Not yet open
Tranilast Vs. Steroids to Prevent Esophageal Stricture (TAPES) After Endoscopic Resection for Superficial Neoplasms
NCT06643689Esophageal Stricture, Esophageal Neoplasms
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
394
Hangzhou, Shaoxing
2025-01-01
Rows per page Showing 801–900 of 1812
Previous 7 8 9 10 11 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/hangzhou?page=9

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,812 of those studies with a site in Hangzhou.

How many clinical trials are recruiting in Hangzhou?

1,096 of the 1,812 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 300 have not yet opened recruitment, 372 are active but closed to new participants, and 44 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.